Hematopoiesis is the process that generates all blood and immune cells, driving immunity, oxygen delivery, and tissue balance. When disrupted, it can cause disorders from anemia to leukemia. This conference will delve into the molecular and cellular mechanisms that control hematopoiesis, highlight cutting-edge technologies, and emphasize their clinical and public health impact. 

Meeting Goals:

Advance Discovery: Present breakthroughs in stem cell biology, transcriptional regulation, and epigenetics using next-gen tools like single-cell multi-omics and CRISPR. 

Translate Research: Bridge basic, translational, and clinical science to speed diagnostics and therapies. 

Build Community: Unite scientists, clinicians, trainees, and industry to spark collaboration across disciplines. 

What Makes This Meeting Unique 

Unlike other hematology meetings, this event spans the full spectrum of hematopoiesis—from stem cell regulation to clinical application—providing a comprehensive, integrated perspective on blood cell development and disease. 

Joint Meeting with “Myeloid Cells” 
A key feature of this year’s event is its joint format with the “Myeloid Cells” meeting. This partnership will provide valuable insights into the interconnected roles of hematopoietic stem cells and myeloid lineages—encompassing monocytes, macrophages, granulocytes, and dendritic cells—in both health and disease. Through shared sessions and networking opportunities, attendees will examine how dysregulation in myeloid cells contributes to pathologies such as chronic inflammation and malignancies, thereby gaining an integrated view of hematopoiesis that offers richer perspectives for future research and therapeutic strategies. 

In the video below, Dr. Anna Beaudin from the University of Utah School of Medicine, talks about what to expect from this meeting and why you should attend:

And, see some of the speaker highlights: